Real-World Data for Predicting Rapid Relapse Triple Negative Cancer: A Study Using NCDB and EHR Data

BackgroundMany patients with triple-negative breast cancer (TNBC), particularly those who are older, Black, or insured by Medicaid, do not receive guideline-concordant treatment, despite its association with up to 4x higher survival. Early identification of patients at risk for rapid relapse may enable timely interventions and improve outcomes. This study applies machine learning (ML) to real-world data to predict risk of rapid relapse in TNBC. MethodsWe trained various ML models (logistic regression, decision trees, random forests, XGBoost, naive Bayes, support vector machines) using National Cancer Database (NCDB) data and fine-tuned them using electronic health record (EHR) data from a cancer registry. Class imbalance was addressed using synthetic minority oversampling technique (SMOTE). Model performance was evaluated using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), receiver operating characteristics area under the curve ROC AUC, accuracy, and F1 scores. Transfer learning, cross-validation, and threshold optimization were applied to enhance the ensemble models performance on clinical data. ResultsInitial models trained on NCDB data exhibited high NPV but low sensitivity and PPV. SMOTE and hyperparameter tuning produced modest improvements. External testing on EHR data from a cancer registry had similar model performance. After applying transfer learning, cross-validation, and threshold optimization using the clinical data, the ensemble model achieved higher performance. The optimized ensemble model achieved a sensitivity of 0.87, specificity of 0.99, PPV of 0.90, NPV of 0.98, ROC AUC of 0.99, accuracy of 0.98, and F1-score of 0.88. This optimized model, leveraging readily available clinical data, demonstrated superior performance compared to initial NCDB-trained models and those reported in extant literature. ConclusionsTransfer learning and threshold optimization effectively adapted ML models trained on NCDB data to an independent real-world clinical dataset from a single site, producing a high-performing model for predicting rapid relapse in TNBC. This model, potentially translatable to fast health interoperability resources (FHIR)-compatible workflows, represents a promising tool for identifying patients at high risk. Future work should include prospective external validation, evaluation of integration into clinical workflows, and implementation studies to determine whether the model improves care processes such as timely patient navigation and treatment planning. Author SummaryIn this study, we set out to understand which patients with triple-negative breast cancer might experience a rapid return of their disease. Many people with this aggressive form of cancer do not receive the treatments that are known to improve survival, especially patients who are older, Black, or insured through public programs. Being able to identify those at highest risk early in their care could help health teams provide timely support and ensure that patients receive the treatments they need. To do this, we used information from a large national cancer database to build computer-based models that learn from patterns in patient data. We then refined these models using real medical records from a cancer center to make sure they worked well in everyday clinical settings. After adjusting and improving the models, we developed a tool that can correctly identify most patients who are likely to have a rapid return of their cancer. Our hope is that this type of tool could eventually be built into routine care and help guide timely follow-up, support services, and treatment planning. More testing in real clinical environments will be important to understand how well the tool improves care and outcomes for patients.